

## **Single-Patient Nurse Mixing Instruction Sheet**

Non-24/7 Pharmacies and Free-Standing Emergency Department

# nitroPRUSSide 50 mg/100 mL D5W

SUPPLIES include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed

### \*\*\*NS flush syringes are never to be used for reconstitution/diluent for medication.\*\*\*

- One (1) nitroPRUSSide 25 mg/mL injection vial
- One (1) D5W 100 mL bag
- Alcohol swabs
- One (1) #18 gauge needle preferred (20-23 gauge needles acceptable)
- One (1) 3 mL sterile IV syringe
- Nursing IV admixture label(s) Lawson # 626

## **STEPS** explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.)

- 1. Wash hands. Prepare/clean the designated mixing area.
- 2. Flip the cap off of the nitroPRUSSide 25 mg/mL injection vial, wipe the rubber stoppers with alcohol swab, and wipe the injection port of the diluent bag.
- 3. Attach #18 gauge needle to syringe, and withdraw 2 mL from the nitroPRUSSide 25 mg/mL injection vial.
- 4. Transfer 2 mL of nitroPRUSSide 25 mg/mL injection into the D5W bag, and discard syringe with needle into a sharp container.
- 5. Gently invert bag to mix. Do not shake. Visually inspect solution (e.g. free of inappropriate visible particulates or other foreign matter, discoloration, and defect), and the container integrity is intact. Discard if any defects.
- 6. Label the nitroPRUSSide 50 mg/100 mL D5W bag with:
  - a. Drug name, strength, and dose (if not apparent by the container)
  - b. Diluent and volume (if not apparent by the container)
  - c. Hang-by date and time (administration must begin within 1 hour from the time of compounding)
  - d. Initials of person compounding

### **NOTES** explicitly state (if applicable) any pertinent information

Protect final product from light. Cover with light protected plastic bag (e.g. brown plastic bag).

#### References

- United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF. Rockville, MD: United States Pharmacopeia.

https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets